NBIX vs. RDY: Neurocrine Biosciences vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

Neurocrine Biosciences (NBIX) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while RDY is classified in Pharmaceuticals.

Neurocrine Biosciences (NBIX) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Neurocrine Biosciences (NBIX) at 20.42% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Neurocrine Biosciences (NBIX) at 18.98% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Neurocrine Biosciences (NBIX) at 41.95% and Dr. Reddy's Laboratories (RDY) at -24.14% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Neurocrine Biosciences (NBIX) at 2.04 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Neurocrine Biosciences (NBIX) at 0.12 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Neurocrine Biosciences (NBIX) at 24.43 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Neurocrine Biosciences (NBIX) at 4.30 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

Valuation Metrics